SCHEMBL6325163

SCHEMBL6325163

OCc1ccc2nc(S)[nH]c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBFB Q13951 6/20 0.52
ALDH1A1 P00352 1/20 0.44
ALOX15 P16050 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
RAD52 P43351 1/20 0.41
UBE2N P61088 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
NT5E P21589 1/20 0.40
PRMT5 O14744 1/20 0.39
S1PR4 O95977 1/20 0.38
S1PR1 P21453 1/20 0.38
S1PR5 Q9H228 1/20 0.38
MAOA P21397 1/20 0.38
DYRK1A Q13627 1/20 0.38
SLC2A1 P11166 1/20 0.37
HSD17B10 Q99714 1/20 0.37
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36
TSHR P16473 1/20 0.36
PLAU P00749 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324712 0.86 HSD17B10 (0.40) CBFBTDP1MAOADYRK1AHSD17B10
SCHEMBL9305459 0.82 ALDH1A1 (0.44) CBFBALDH1A1ALOX15RAD52UBE2N
SCHEMBL10707113 0.79 TUBB4A (0.45) ALDH1A1ALOX15RAD52UBE2NS1PR4
SCHEMBL6467818 0.79 CBFB (0.52) CBFBALDH1A1ALOX15TDP1RAD52
SCHEMBL4226862 0.79 ALDH1A1 (0.56) CBFBALDH1A1ALOX15TDP1MAOA
SCHEMBL727388 0.79 PLAU (0.61) CBFBALDH1A1ALOX15TDP1RAD52
SCHEMBL17309628 0.78 ALDH1A1 (0.41) CBFBALDH1A1ALOX15RAD52UBE2N
SCHEMBL8083831 0.77 TUBB4A (0.55) S1PR4S1PR1S1PR5TSHR
SCHEMBL14557086 0.76 S1PR4 (0.45) ALDH1A1ALOX15TDP1RAD52UBE2N
SCHEMBL13438570 0.76 SLC2A1 (0.42) CBFBALDH1A1ALOX15RAD52UBE2N

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180203353-A1 CURED FILM AND METHOD FOR MANUFACTURING SAME TORAY INDUSTRIES, INC. (JP) 2018-07-19 US disclosed
US-20180066107-A1 PHOTOSENSITIVE RESIN COMPOSITION TORAY INDUSTRIES, INC. (JP) 2018-03-08 US disclosed
CN-1642941-A 1-N-aminobenzimidazole derivatives ZERIA PHARM CO LTD (JP) 2005-07-20 CN disclosed
US-20050148634-A1 1-N-Aminobenzimidazole derivatives ZERIA PHARMACEUTICAL CO., LTD (JP) 2005-07-07 US disclosed
US-6906078-B2 Method of using (H+/K+) ATPase inhibitors as antiviral agents PHARMACIA CORPORATION (US) 2005-06-14 US disclosed
US-6642264-B1 Thiazolo(3,2-a)benzoimidazole derivatives act specifically on metabotropic glutamate receptors and are used as medicaments. YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2003-11-04 US disclosed
CN-1120842-C New thiazole benzimidazole derivative YAMANOUCHI PHARMA CO LTD (JP) 2003-09-10 CN disclosed
EP-1167369-A1 NOVEL THIAZOLOBENZIMIDAZOLE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2002-01-02 EP disclosed
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents MOORMAN ALAN E (US) 2001-11-29 US disclosed
WO-2001034573-A1 COMPOUNDS ASTRAZENECA AB (SE) 2001-05-17 WO disclosed
CN-1271731-A New thiazole benzimidazole derivative YAMANOUCHI PHARMA CO LTD (JP) 2000-11-01 CN disclosed
US-5945425-A ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE G.D. SEARLE & CO. (US) 1999-08-31 US disclosed
EP-0457331-B1 Piperidine derivatives and antiulcer composition containing the same MEIJI SEIKA KAISHA (JP) 1996-11-20 EP disclosed
WO-1995029897-A1 METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS G.D. SEARLE & CO. (US) 1995-11-09 WO disclosed
US-5185347-A PIPERIDINE COMPOUNDS AND ANTIULCER COMPOSITION CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 1993-02-09 US disclosed
EP-0457331-A1 Piperidine derivatives and antiulcer composition containing the same MEIJI SEIKA KAISHA LTD. (JP) 1991-11-21 EP disclosed
US-4772619-A ANTIULCER AGENTS G. D. SEARLE & CO. (US) 1988-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148634-A1 1-N-Aminobenzimidazole derivatives CYP1B1, CYP2E1, CYP1A1 CBFB 755/4885ALDH1A1 57/4885ALOX15 283/4885
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents ATP4A, ATP1A1, ATP1A4 CBFB 2862/4885ALDH1A1 2148/4885ALOX15 3259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.